623 related articles for article (PubMed ID: 24615402)
1. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.
Isikbay M; Otto K; Kregel S; Kach J; Cai Y; Vander Griend DJ; Conzen SD; Szmulewitz RZ
Horm Cancer; 2014 Apr; 5(2):72-89. PubMed ID: 24615402
[TBL] [Abstract][Full Text] [Related]
2. Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic.
Sherk AB; Frigo DE; Schnackenberg CG; Bray JD; Laping NJ; Trizna W; Hammond M; Patterson JR; Thompson SK; Kazmin D; Norris JD; McDonnell DP
Cancer Res; 2008 Sep; 68(18):7475-83. PubMed ID: 18794135
[TBL] [Abstract][Full Text] [Related]
3. Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy.
O'Neill D; Jones D; Wade M; Grey J; Nakjang S; Guo W; Cork D; Davies BR; Wedge SR; Robson CN; Gaughan L
Oncotarget; 2015 Sep; 6(28):26029-40. PubMed ID: 26267320
[TBL] [Abstract][Full Text] [Related]
4. Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers.
Szmulewitz RZ; Chung E; Al-Ahmadie H; Daniel S; Kocherginsky M; Razmaria A; Zagaja GP; Brendler CB; Stadler WM; Conzen SD
Prostate; 2012 Feb; 72(2):157-64. PubMed ID: 21563193
[TBL] [Abstract][Full Text] [Related]
5. Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth.
Kach J; Long TM; Selman P; Tonsing-Carter EY; Bacalao MA; Lastra RR; de Wet L; Comiskey S; Gillard M; VanOpstall C; West DC; Chan WC; Griend DV; Conzen SD; Szmulewitz RZ
Mol Cancer Ther; 2017 Aug; 16(8):1680-1692. PubMed ID: 28428441
[TBL] [Abstract][Full Text] [Related]
6. The Dual Androgen Receptor and Glucocorticoid Receptor Antagonist CB-03-10 as Potential Treatment for Tumors that have Acquired GR-mediated Resistance to AR Blockade.
Rosette C; Agan FJ; Rosette N; Mazzetti A; Moro L; Gerloni M
Mol Cancer Ther; 2020 Nov; 19(11):2256-2266. PubMed ID: 32847976
[TBL] [Abstract][Full Text] [Related]
7. Radiation-induced glucocorticoid receptor promotes CD44+ prostate cancer stem cell growth through activation of SGK1-Wnt/β-catenin signaling.
Chen F; Chen X; Ren Y; Weng G; Keng PC; Chen Y; Lee SO
J Mol Med (Berl); 2019 Aug; 97(8):1169-1182. PubMed ID: 31187175
[TBL] [Abstract][Full Text] [Related]
8. Role for the kinase SGK1 in stress, depression, and glucocorticoid effects on hippocampal neurogenesis.
Anacker C; Cattaneo A; Musaelyan K; Zunszain PA; Horowitz M; Molteni R; Luoni A; Calabrese F; Tansey K; Gennarelli M; Thuret S; Price J; Uher R; Riva MA; Pariante CM
Proc Natl Acad Sci U S A; 2013 May; 110(21):8708-13. PubMed ID: 23650397
[TBL] [Abstract][Full Text] [Related]
9. Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease.
Smith R; Liu M; Liby T; Bayani N; Bucher E; Chiotti K; Derrick D; Chauchereau A; Heiser L; Alumkal J; Feiler H; Carroll P; Korkola JE
Sci Rep; 2020 Dec; 10(1):21750. PubMed ID: 33303959
[TBL] [Abstract][Full Text] [Related]
10. Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.
Skor MN; Wonder EL; Kocherginsky M; Goyal A; Hall BA; Cai Y; Conzen SD
Clin Cancer Res; 2013 Nov; 19(22):6163-72. PubMed ID: 24016618
[TBL] [Abstract][Full Text] [Related]
11. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.
Xie N; Cheng H; Lin D; Liu L; Yang O; Jia L; Fazli L; Gleave ME; Wang Y; Rennie P; Dong X
Int J Cancer; 2015 Feb; 136(4):E27-38. PubMed ID: 25138562
[TBL] [Abstract][Full Text] [Related]
12. Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality.
Yemelyanov A; Bhalla P; Yang X; Ugolkov A; Iwadate K; Karseladze A; Budunova I
Cell Cycle; 2012 Jan; 11(2):395-406. PubMed ID: 22223138
[TBL] [Abstract][Full Text] [Related]
13. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
Qi W; Morales C; Cooke LS; Johnson B; Somer B; Mahadevan D
Oncotarget; 2015 Dec; 6(39):41976-87. PubMed ID: 26506516
[TBL] [Abstract][Full Text] [Related]
14. TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.
Palit SA; Vis D; Stelloo S; Lieftink C; Prekovic S; Bekers E; Hofland I; Šuštić T; Wolters L; Beijersbergen R; Bergman AM; Győrffy B; Wessels LF; Zwart W; van der Heijden MS
Elife; 2019 Dec; 8():. PubMed ID: 31855178
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.
Stringer-Reasor EM; Baker GM; Skor MN; Kocherginsky M; Lengyel E; Fleming GF; Conzen SD
Gynecol Oncol; 2015 Sep; 138(3):656-62. PubMed ID: 26115975
[TBL] [Abstract][Full Text] [Related]
16. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
17. Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor.
Adelaiye-Ogala R; Gryder BE; Nguyen YTM; Alilin AN; Grayson AR; Bajwa W; Jansson KH; Beshiri ML; Agarwal S; Rodriguez-Nieves JA; Capaldo B; Kelly K; VanderWeele DJ
Mol Cancer Ther; 2020 Jul; 19(7):1436-1447. PubMed ID: 32371590
[TBL] [Abstract][Full Text] [Related]
18. SGK1 inhibition induces autophagy-dependent apoptosis via the mTOR-Foxo3a pathway.
Liu W; Wang X; Liu Z; Wang Y; Yin B; Yu P; Duan X; Liao Z; Chen Y; Liu C; Li X; Dai Y; Tao Z
Br J Cancer; 2017 Oct; 117(8):1139-1153. PubMed ID: 29017179
[TBL] [Abstract][Full Text] [Related]
19. A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.
Kuruma H; Matsumoto H; Shiota M; Bishop J; Lamoureux F; Thomas C; Briere D; Los G; Gleave M; Fanjul A; Zoubeidi A
Mol Cancer Ther; 2013 May; 12(5):567-76. PubMed ID: 23493310
[TBL] [Abstract][Full Text] [Related]
20. Agonist-specific Protein Interactomes of Glucocorticoid and Androgen Receptor as Revealed by Proximity Mapping.
Lempiäinen JK; Niskanen EA; Vuoti KM; Lampinen RE; Göös H; Varjosalo M; Palvimo JJ
Mol Cell Proteomics; 2017 Aug; 16(8):1462-1474. PubMed ID: 28611094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
